Alaunos Therapeutics
TCRTNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $1.71 Prior regular-session close from the quote source.
- $1.60–$1.73 Regular-session low and high so far today.
- 93.8K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $0.72–$4.50 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own TCRT if Alaunos is an option on a preclinical oral small-molecule obesity/MASLD pipeline, but the investable case depends first on financing or partnership survival and only second on scientific upside.
TCRT price history
Loading recent earnings…
Investment thesis
What must happen next
The pipeline option has value only if Alaunos secures financing, a partner, or another non-dilutive source of capital before liquidity, rather than science, determines the outcome.WeakeningMateriality: High
Cash and cash equivalents were $1.385 million at FY2025 year-end, confirming that liquidity is a central constraint rather than a background issue. If this holds, existing shareholders retain exposure to drug-development upside; if it breaks, dilution or restructuring can absorb most of the upside even if the science remains interesting.
Watch: Alaunos fails to announce a financing, partnership, license, or strategic transaction before the next material cash need.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash and cash equivalents were $1.385 million at FY2025 year-end, confirming that liquidity is a central constraint rather than a.
Open source ↗Alaunos must keep development spending asset-light until it has external validation, because rebuilding a full biotech cost structure would consume the remaining option value before the lead program can mature.StrengtheningMateriality: High
Annual GAAP operating cash flow was negative $2.869 million in FY2025 versus negative $4.971 million in FY2024 and negative $30.142 million in FY2023, showing major burn reduction. Disciplined burn keeps the company alive long enough to test the thesis; uncontrolled spend makes shareholder returns dependent on repeated dilution.
Watch: Management restarts large internal R&D, manufacturing, or clinical infrastructure before securing outside capital.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Annual GAAP operating cash flow was negative $2.869 million in FY2025 versus negative $4.971 million in FY2024 and negative $30.142.
Open source ↗The obesity/MASLD strategy must show a credible reason an oral small-molecule therapeutic can compete for capital against better-funded incretin, amylin, obesity, and MASH/MASLD programs.HoldingMateriality: Medium
The company describes itself as focused on novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, including MASLD. Differentiation is what turns a preclinical idea into partnerable intellectual property; without it, Alaunos is competing for scarce biotech capital with no commercial leverage.
Watch: Novo Nordisk, Eli Lilly, Viking Therapeutics, Structure Therapeutics, Zealand Pharma, Roche/Carmot, or other metabolic-disease competitors publish oral or injectable data that make Alaunos’ target profile commercially irrelevant.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company describes itself as focused on novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, including MASLD.
Open source ↗Because Alaunos has no meaningful commercial revenue base, the value-creation path must come from partnership, licensing, acquisition interest, or capital-market validation rather than customer demand for a current product.StrengtheningMateriality: Medium
Annual GAAP revenue was only $5,000 in FY2025, down from $10,000 in FY2024 and far below the $2.922 million reported in FY2022. Investors should judge the company as a financing-and-development milestone story, not as a revenue compounding business.
Watch: No partner, licensee, acquirer, or institutional financing source validates the obesity/MASLD program after additional data disclosure.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Annual GAAP revenue was only $5,000 in FY2025, down from $10,000 in FY2024 and far below the $2.922 million reported.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
The pipeline option has value only if Alaunos secures financing, a partner, or another non-dilutive source of capital before liquidity, rather than science, determines the outcome. If this holds, existing shareholders retain exposure to drug-development upside; if it breaks, dilution or restructuring can absorb most of the upside even if the science remains interesting.
Alaunos must keep development spending asset-light until it has external validation, because rebuilding a full biotech cost structure would consume the remaining option value before the lead program can mature. Disciplined burn keeps the company alive long enough to test the thesis; uncontrolled spend makes shareholder returns dependent on repeated dilution.
The obesity/MASLD strategy must show a credible reason an oral small-molecule therapeutic can compete for capital against better-funded incretin, amylin, obesity, and MASH/MASLD programs. Differentiation is what turns a preclinical idea into partnerable intellectual property; without it, Alaunos is competing for scarce biotech capital with no commercial leverage.
Because Alaunos has no meaningful commercial revenue base, the value-creation path must come from partnership, licensing, acquisition interest, or capital-market validation rather than customer demand for a current product. Investors should judge the company as a financing-and-development milestone story, not as a revenue compounding business.
All standing thesis claims
Original report summary
Alaunos is an option on a preclinical oral small-molecule obesity/MASLD pipeline, but the investable case depends first on financing or partnership survival and only second on scientific upside.
Bull case and bear case
Bull case and bear case for Alaunos Therapeutics
Where the evidence on Alaunos Therapeutics disagrees: Mixed on the latest evidence (Oct 13, 2026). Of its 4 thesis points, 2 strengthening, 1 holding and 1 weakening.
Bull case: what the evidence supports
Alaunos must keep development spending asset-light until it has external validation, because rebuilding a full biotech cost structure would consume the remaining option value before the lead program can mature.
The obesity/MASLD strategy must show a credible reason an oral small-molecule therapeutic can compete for capital against better-funded incretin, amylin, obesity, and MASH/MASLD programs.
Because Alaunos has no meaningful commercial revenue base, the value-creation path must come from partnership, licensing, acquisition interest, or capital-market validation rather than customer demand for a current product.
Bear case: what the evidence questions
The pipeline option has value only if Alaunos secures financing, a partner, or another non-dilutive source of capital before liquidity, rather than science, determines the outcome.
Thesis-Break Engine
Thesis-break watch · Alaunos Therapeutics
Loading the break-condition record for Alaunos Therapeutics.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedCompleted an acquisition or disposition of assets.
Alaunos Therapeutics filed an SEC 8-K on 2026-10-13: Completed an acquisition or disposition of assets. It is a dated development that tests the current thesis.
- MixedDelisting notice or listing-rule failure.
Alaunos Therapeutics filed an SEC 8-K on 2026-10-09: Delisting notice or listing-rule failure. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Alaunos Therapeutics filed an SEC 8-K on 2026-09-22: Entered a material definitive agreement. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Alaunos fails to announce a financing, partnership, license, or strategic transaction before the next material cash need.
- Management restarts large internal R&D, manufacturing, or clinical infrastructure before securing outside capital.
- Novo Nordisk, Eli Lilly, Viking Therapeutics, Structure Therapeutics, Zealand Pharma, Roche/Carmot, or other metabolic-disease competitors publish oral or injectable data that make Alaunos’ target profile commercially irrelevant.
- No partner, licensee, acquirer, or institutional financing source validates the obesity/MASLD program after additional data disclosure.
TCRT news
Loading headlines…
Financial statements
TCRT income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
TCRT: quick answers
- What is TCRT's short interest?
- As of October 30, 2026, 184,372 TCRT shares were sold short, down 77.5% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. TCRT short interest history